title: [Effectiveness of postoperative adjuvant chemotherapy using S-1 plus CDDP for type 4 gastric cancer].
abstract: BACKGROUND
  Our aim was to evaluate postoperative adjuvant chemotherapy using S-1 plus cisplatin(S-1/CDDP)for type 4 gastric cancer.
  
  
  METHODS
  We investigated 18 patients who had undergone curative operations for type 4 gastric cancer. They were classified into two groups of patients, one using S-1/CDDP(group A: 9)and one using S-1 alone(group B: 9), after surgery between 2000 and 2010. Median survival time(MST)and survival rates were reported retrospectively. Patients as- signed to group A were treated with the following regimen: S-1, 80-120mg/day(body surface area 1. 25m2>: 80mg/day, 1. 25-1. 5m2: 100mg/day, 1. 5m2<: 120mg), was administered for 21 consecutive days followed by a 14-day rest period, and CDDP, 60mg/m2, was administered on day 8 for 5 courses. After this course, S-1 80mg/m2 was given for 18 months. S- 1(80-120mg/day, body surface area 1. 25m2>: 80mg/day, 1. 25-1. 5m2: 100mg/day, 1. 5m2<: 120mg)was administered for 28 days followed by 14-day rest as one course.
  
  
  RESULTS
  MST differed significantly between group A and group B (MST; group A: 1, 603 vs group B: 955 days). The overall survival rate at 5 years was 64. 8% in group A and 13% in group B, and the overall survival rate in group A was statistically better than that in group B(p=0. 02).
  
  
  CONCLUSIONS
  Postoperative adjuvant chemotherapy using S-1/CDDP for resected type 4 gastric cancer contributes to prolonged life, compared with using S-1 in overall survival.
authors.affiliation: Dept. of Surgery, Fukui Prefectural Hospital, Japan.
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asaumi
authors.forename: Tamon
authors.initials: T
authors.lastname: Miyanaga
authors.forename: Osamu
authors.initials: O
authors.lastname: Hosokawa
authors.forename: Yoji
authors.initials: Y
authors.lastname: Nishida
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Satsuki
authors.initials: S
authors.lastname: Shimizu
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Tanaka
authors.forename: Tomoko
authors.initials: T
authors.lastname: Ito
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sato
authors.forename: Yasumitsu
authors.initials: Y
authors.lastname: Hirano
authors.forename: Kazuya
authors.initials: K
authors.lastname: Maeda
authors.forename: Koji
authors.initials: K
authors.lastname: Ota
authors.forename: Kenji
authors.initials: K
authors.lastname: Doden
authors.forename: Masakazu
authors.initials: M
authors.lastname: Hattori
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hashizume
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin